We are monitoring the impact of COVID-19 on Middle East & Africa Next Generation Antibody Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5235
Share on
Share on

Middle East & Africa Next Generation Antibody Therapeutics Market Research Report - Segmented By Therapeutics, Technology & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, Growth, Forecast | 2021 to 2026

Pulished: April, 2021
ID: 5235
Pages: 145

Middle East & Africa Next Generation Antibody Therapeutics Market Size & Growth (2021 to 2026):

As Per the Report, the Middle East & Africa Next Generation Antibody Therapeutics Market size is valued at USD 0.32 billion in 2021 and is expected to grow at a CAGR of 2.6% to reach USD 0.36 billion by 2026 during the forecast period 2021 to 2026. It captures 8% of the global market share.

Next generation antibody therapeutics have high efficiency and are safer. Rapid advancements in monoclonal antibodies technology are the reason for this. These advances have improved bifunctional properties, decreased functional size along with immunogenicity. Several medical conditions like cancer; autoimmune diseases, etc. are treated using these technologies because of its enhanced properties.

A rising number of cases of chronic diseases, rapid advancements in technology, higher investment in R&D and increasing healthcare expenditure are the primary drivers of market growth. On the other hand, strict administrative guidelines and regulatory requirements and inordinate delays in approval for new drugs along with their high costs are the primary restraints of market growth.

Middle East & Africa Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories

  • By Therapeutics: Oncology and Autoimmune/Inflammatory Diseases
  • By Technology: Antibody-Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-like Proteins, and Biosimilar Antibody Products.
  • By Country: KSA, UAE, Israel, the rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA.

On the basis of region, MEA continues to be the least attractive market in the forecast period.

Key Market Companies dominating the Middle East & Africa Next Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.

1. Introduction       

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods

                1.4 General Study Assumptions                

2. Research Methodology                 

                2.1 Introduction     

                2.2 Research Phases                      

      2.2.1 Secondary Research           

      2.2.2 Primary Research 

      2.2.3 Econometric Modelling      

      2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline

3. Overview             

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemiology    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

                4.1 Market Drivers

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market    

5. Market Segmentation                    

                5.1 Technology                 

      5.1.1 Introduction           

      5.1.2 Antibody-Drug Conjugates (ADCs)               

      5.1.3 Bispecific Antibodies (BsAbs)          

      5.1.4 Fc Engineered Antibodies 

      5.1.5 Antibody Fragments and Antibody-like Proteins    

      5.1.6 Biosimilar Antibody Products          

      5.1.7 Y-o-Y Growth Analysis, By Technology        

      5.1.8 Market Attractiveness Analysis, By Technology      

      5.1.9 Market Share Analysis, By Technology        

                5.2 Therapeutic Application                        

      5.2.1 Introduction           

      5.2.2 Oncology 

      5.2.3 Autoimmune/Inflammatory Diseases         

      5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application               

      5.2.5 Market Attractiveness Analysis, By Therapeutic Application             

      5.2.6 Market Share Analysis, By Therapeutic Application               

6. Geographical Analysis                    

                6.1 Introduction     

      6.1.1 Regional Trends    

      6.1.2 Impact Analysis     

      6.1.3 Y-o-Y Growth Analysis        

                      6.1.3.1 By Geographical Area

                      6.1.3.2 By Technology

                      6.1.3.3 By Therapeutic Application

      6.1.4  Market Attractiveness Analysis     

                      6.1.4.1 By Geographical Area

                      6.1.4.2 By Technology

                      6.1.4.3 By Therapeutic Application

      6.1.5  Market Share Analysis      

                      6.1.5.1 By Geographical Area

                      6.1.5.2 By Technology

                      6.1.5.3 By Therapeutic Application

                6.2 Middle-East      

                6.3 Africa  

7. Strategic Analysis             

                7.1 PESTLE analysis                         

      7.1.1 Political     

      7.1.2 Economic 

      7.1.3 Social         

      7.1.4 Technological         

      7.1.5 Legal          

      7.1.6 Environmental       

                7.2 Porter’s Five analysis    

      7.2.1 Bargaining Power of Suppliers        

      7.2.2 Bargaining Power of Consumers    

      7.2.3 Threat of New Entrants     

      7.2.4 Threat of Substitute Products and Services              

      7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis              

                8.1 Roche 

      8.1.1 Overview 

      8.1.2 Product Analysis   

      8.1.3 Financial analysis  

      8.1.4 Recent Developments       

      8.1.5 SWOT analysis       

      8.1.6 Analyst View          

                8.2 Seattle Genetics                       

                8.3 Takeda                         

                8.4 Dyax Corp.                  

                8.5 Immunogen     

                8.6 Amgen, Inc.      

                8.7 Biogen

                8.8 Kyowa Hakko Kirin Co., Ltd.                 

                8.9 AstraZeneca     

                8.10 Pfizer, Inc.                

9. Competitive Landscape                 

                9.1 Market share analysis  

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, Collaborations, and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities               

Appendix                 

                a) List of Tables                

                b) List of Figures    

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type by Technology market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East and Africa Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  2. Middle East and Africa Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  3. Middle East and Africa Bispecific Antibodies (BsAbs) Market By Region, From 2021 to 2026 ( USD Billion )
  4. Middle East and Africa Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  5. Middle East and Africa Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  6. Middle East and Africa Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  7. Middle East and Africa Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  8. Middle East and Africa Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  9. Middle East and Africa Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  10. Middle East Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  11. Middle East Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  12. Africa Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  13. Africa Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample